Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,358.55
  • Today's Change14.55 / 1.08%
  • Shares traded14.13k
  • 1 Year change+65.88%
  • Beta0.6501
Data delayed at least 20 minutes, as of Jul 29 2021 10:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Aug-20
  • 20-May-21
  • 17-Jun-21
  • 15-Jul-21
  • 22-Jul-21
Select bar for recommendation details.
Recommendations22-Jul-21
Buy2
Outperform3
Hold2
Underperform0
Sell0

Share price forecast

The 7 analysts offering 12 month price targets for Oxford BioMedica plc have a median target of 1,450.00, with a high estimate of 2,150.00 and a low estimate of 1,007.00. The median estimate represents a 7.89% increase from the last price of 1,344.00.
High60.0%2,150.00
Med7.9%1,450.00
Low-25.1%1,007.00

Earnings history & estimates

Oxford BioMedica plc reported annual 2020 losses of -6.82 per share on Apr 15, 2021.
Average growth rate+58.36%
More ▼

Revenue history & estimates

Oxford Biomedica plc had revenues for the full year 2020 of 87.73m. This was 36.95% above the prior year's results.
Average growth rate+36.46%
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.